Reply: Fixed 3.7-GBq <sup>131</sup>I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History

Deandreis, Désirèe

doi:10.2967/jnumed.117.193185

J Nucl Med

2017

DOI: 10.2967/jnumed.117.193185

|View full text |Cite

Reply: Fixed 3.7-GBq ¹³¹I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History

Désirèe Deandreis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects

Shah,

Dabhade,

Bharadia

et al. 2024

Zeitschrift Für Naturforschung C

View full text Add to dashboard Cite

Theranostics refers to the combination of diagnostic biomarkers with therapeutic agents that share a specific target expressed by diseased cells and tissues. Nuclear medicine is an exciting component explored for its applicability in theranostic concepts in clinical and research investigations. Nuclear theranostics is based on the employment of radioactive compounds delivering ionizing radiation to diagnose and manage certain diseases employing binding with specifically expressed targets. In the realm of personalized medicine, nuclear theranostics stands as a beacon of potential, potentially revolutionizing disease management. Studies exploring the theranostic profile of radioactive compounds have been presented in this review along with a detailed explanation of radioactive compounds and their theranostic applicability in several diseases. It furnishes insights into their applicability across diverse diseases, elucidating the intricate interplay between these compounds and disease pathologies. Light is shed on the important milestones of nuclear theranostics beginning with radioiodine therapy in thyroid carcinomas, MIBG labelled with iodine in neuroblastoma, and several others. Our perspectives have been put forth regarding the most important theranostic agents along with emerging trends and prospects.

show abstract

Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects

Shah,

Dabhade,

Bharadia

et al. 2024

Zeitschrift Für Naturforschung C

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Reply: Fixed 3.7-GBq ¹³¹I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History

Cited by 1 publication

References 5 publications

Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects

Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects

Contact Info

Product

Resources

About

Reply: Fixed 3.7-GBq 131I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History

Cited by 1 publication

References 5 publications

Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects

Navigating the landscape of theranostics in nuclear medicine: current practice and future prospects

Contact Info

Product

Resources

About

Reply: Fixed 3.7-GBq ¹³¹I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History